The stock of Johnson & Johnson (NYSE: JNJ) has decreased by -0.23 when compared to last closing price of 154.93. Despite this, the company has experienced a -1.84% fall in its stock price over the last five trading sessions. globenewswire.com reported 2025-04-26 that First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumours, demonstrating the potential for bladder preservation with 94 percent of patients avoiding radical cystectomy 1
Is It Worth Investing in Johnson & Johnson (NYSE: JNJ) Right Now?
Johnson & Johnson (NYSE: JNJ) has a higher price-to-earnings ratio of 17.18x compared to its average ratio. JNJ has 36-month beta value of 0.42. Analysts have mixed views on the stock, with 8 analysts rating it as a “buy,” 4 as “overweight,” 13 as “hold,” and 0 as “sell.”
The public float for JNJ is 2.41B, and currently, short sellers hold a 0.87% ratio of that float. The average trading volume of JNJ on April 28, 2025 was 9.91M shares.
JNJ’s Market Performance
The stock of Johnson & Johnson (JNJ) has seen a -1.84% decrease in the past week, with a -4.42% drop in the past month, and a 5.29% gain in the past quarter. The volatility ratio for the week is 1.67%, and the volatility levels for the past 30 days are at 2.84% for JNJ. The simple moving average for the past 20 days is -0.34% for JNJ’s stock, with a -1.53% simple moving average for the past 200 days.
Analysts’ Opinion of JNJ
Many brokerage firms have already submitted their reports for JNJ stocks, with BofA Securities repeating the rating for JNJ by listing it as a “Neutral.” The predicted price for JNJ in the upcoming period, according to BofA Securities is $166 based on the research report published on December 10, 2024 of the previous year 2024.
Wolfe Research, on the other hand, stated in their research note that they expect to see JNJ reach a price target of $190. The rating they have provided for JNJ stocks is “Outperform” according to the report published on November 15th, 2024.
Daiwa Securities gave a rating of “Neutral” to JNJ, setting the target price at $150 in the report published on July 23rd of the previous year.
JNJ Trading at -3.27% from the 50-Day Moving Average
After a stumble in the market that brought JNJ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.07% of loss for the given period.
Volatility was left at 2.84%, however, over the last 30 days, the volatility rate increased by 1.67%, as shares sank -5.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.44% lower at present.
During the last 5 trading sessions, JNJ fell by -1.84%, which changed the moving average for the period of 200-days by +5.12% in comparison to the 20-day moving average, which settled at $155.11. In addition, Johnson & Johnson saw 6.89% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at JNJ starting from Decker Robert J, who sale 6,999 shares at the price of $165.88 back on Feb 25 ’25. After this action, Decker Robert J now owns 21,001 shares of Johnson & Johnson, valued at $1,160,994 using the latest closing price.
Decker Robert J, the Officer of Johnson & Johnson, proposed sale 6,999 shares at $165.88 during a trade that took place back on Feb 25 ’25, which means that Decker Robert J is holding shares at $1,161,010 based on the most recent closing price.
Stock Fundamentals for JNJ
Current profitability levels for the company are sitting at:
- 0.25 for the present operating margin
- 0.68 for the gross margin
The net margin for Johnson & Johnson stands at 0.24. The total capital return value is set at 0.16. Equity return is now at value 29.45, with 11.93 for asset returns.
Based on Johnson & Johnson (JNJ), the company’s capital structure generated 0.4 points at debt to capital in total, while cash flow to debt ratio is standing at 0.47. The debt to equity ratio resting at 0.67. The interest coverage ratio of the stock is 27.46.
Currently, EBITDA for the company is 24.78 billion with net debt to EBITDA at 0.4. When we switch over and look at the enterprise to sales, we see a ratio of 4.32. The receivables turnover for the company is 5.58for trailing twelve months and the total asset turnover is 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.26.
Conclusion
To put it simply, Johnson & Johnson (JNJ) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
